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The retinoblastoma protein: multitasking
to suppress tumorigenesis
Tinke L. Vormer1, Jacob B Hansen2, and Hein te Riele1,*
1Division of Biological Stress Response; The Netherlands Cancer Institute; Amsterdam, The Netherlands; 2Department of Biology; University of Copenhagen;
Copenhagen, Denmark
Tumor suppressor activity of the retinoblastoma protein pRB is preserved despite loss of interaction with E2F
transcription factors (E2F) or proteins harboring a leucine-x-cysteine-x-glutamic acid motif (LxCxE, where x is any amino
acid). This indicates that pRB uses several parallel pathways to suppress tumorigenesis, which may also include E2F- and
LxCxE-independent interactions.
A frequent event in tumor develop-
ment is loss of the retinoblastoma tumor
suppressor gene, RB1, or altered activity
of upstream regulators that inactivate its
product, the retinoblastoma protein
(pRB). pRB and its 2 family members,
p130 and p107, collectively known as
pocket proteins, play key roles during the
G1 phase of the cell cycle, when they
inhibit the E2F family of DNA binding
transcription factors (E2F). Many studies
have shown that expression of E2F target
genes is essential for cell cycle progression
and proliferation.1 Binding to pocket pro-
teins blocks the transactivation domain
(TAD) of E2F and hence E2F-dependent
transcription. In addition, pocket proteins
can recruit chromatin-remodeling com-
plexes to promoters of E2F target genes
through their capacity to simultaneously
bind E2F proteins and proteins harboring
a leucine-x-cysteine-x-glutamic acid motif
(LxCxE, where x is any amino acid).2
Pocket protein chromatin remodeling
complexes have been implicated in pro-
cesses thought to be critical for tumor sup-
pression such as (irreversible) cell cycle
arrest in response to antiproliferative sig-
nals and oncogene-induced senescence.3
Thus, both pRB-mediated inhibition of
E2F-dependent transcription and pRB-
LxCxE–mediated active silencing of E2F
target genes were expected to be essential
for tumor suppression. Recent studies
question this assumption.
To dissect the contribution of different
pRB functions to cell cycle control and
tumor suppression, pRB mutants have
been created in which a specific function
was abrogated. Our laboratory and others
generated pRB mutants that are unable to
bind LxCxE-containing proteins while
retaining the ability to inhibit E2F-medi-
ated transcription. Cells expressing these
mutant proteins, collectively designated
pRBDLxCxE, displayed normal arrest in
response to serum deprivation whereas
arrest in response to DNA damage or
expression of a constitutively active RAS
oncogene was impaired.4–6 Importantly,
spontaneous tumor formation was not
observed in RbDLxCxE/DLxCxE mice.4–6 This
sharply contrasts with RbC/¡ mice, which
develop pituitary tumors at an early age,
suggesting that interaction between pocket
proteins and LxCxE-containing proteins by
itself is not crucial for tumor suppression.
The question then arises of whether
inhibition of E2F transactivation by pRB is
critical for tumor suppression. A recent
report from the Dick laboratory describes a
pRB mutant, pRBDG, that is impaired in
binding the transactivation domain of
E2Fs via the pocket region and therefore,
by current consensus, is incapable of inhib-
iting E2F-dependent transcription.7 As
recruitment of pRBDG to E2F binding sites
in target promoters is prohibited, active
repression of E2F target genes seems also
ablated, despite the retained ability of this
mutant to interact with LxCxE-containing
proteins. Remarkably, pRBDG, although
largely incapable of regulating E2F activity,
still acted as a tumor suppressor in mice.
Taken together, these studies show that
the loss of pRB’s ability to interact with
LxCxE proteins or with the E2F transacti-
vation domain does not promote sponta-
neous tumor formation in mice. In the
first case, pRB-E2F interactions are main-
tained leaving open the possibility that
regulation of E2F-mediated transactiva-
tion is sufficient for tumor suppression. In
the second case, pRB-LxCxE interactions,
independent of E2Fs, are maintained. It is
therefore possible that these E2F-indepen-
dent LxCxE interactions represent a third
mechanism by which pRB counteracts
proliferation and tumorigenesis. On one
extreme, this could imply that E2F regula-
tion is totally dispensable for pRB-medi-
ated tumor suppression. Alternatively, it is
possible that each of these mechanisms on
its own is capable of suppressing tumori-
genesis and hence all 3 mechanisms need
to be ablated to reveal a tumor susceptibil-
ity phenotype (Fig. 1).
Is there evidence that pRB–LxCxE
interactions independent of E2Fs could
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suppress tumorigenesis? In vitro experi-
ments have shown that cell cycle arrest
upon g-irradiation was normal in cells
expressing pRBDG but attenuated in those
expressing pRBDLxCxE, suggesting the
involvement of pRB–LxCxE interactions
independent of E2F binding.4,7 Such
interactions may also mediate cell cycle
arrest in response to activated RAS.4
LxCxE-dependent interactions between
pRB and replication factors (DNA poly-
merase d, RFC-p145) have been reported2
and pRB was found to be recruited to ori-
gins of replication in response to DNA
damage.8 Although others have ques-
tioned a direct involvement of pRB in
DNA replication,9 these observations may
point to a role for pRB in the DNA dam-
age response, possibly providing a tumor
suppressive mechanism independent of
E2F regulation. The contribution of such
a mechanism can be tested by combining
the mutations in pRB that abrogate inter-
actions with E2F and with LxCxE-con-
taining proteins, thereby creating pRBDG-
DLxCxE, and investigating whether this
double mutant protein can suppress devel-
opment of pituitary tumors in mice.
Should RbDG-DLxCxE/C mice remain
refractory to spontaneous tumorigenesis,
a fourth tumor suppressive activity of
pRB must be envisaged that acts parallel
to pRB activities relying on binding of
E2F and LxCxE. Such a mechanism
could involve the interaction of E2F
transcription factor 1 (E2F1) and the
C-terminus of pRB. This interaction is
fundamentally different from the gen-
eral pRB–E2F interaction that blocks
the E2F transactivation domain, is
unique for E2F1, and was suggested to
specifically function in the induction of
proapoptotic genes in response to DNA
damage and possibly oncogenic stress.10
To analyze whether this mechanism can
contribute to tumor suppression, it will
be interesting to test whether suppres-
sion of apoptosis exposes a tumor sus-
ceptibility phenotype of the described
pRB mutants. One approach is to gen-
erate RbDG-DLxCxE/C mice overexpressing
B-cell lymphoma 2 (BCL2) in the pitu-
itary intermediate lobe. Alternatively,
yet unidentified functions of pRB could
mediate its tumor suppressor role.
Immunoprecipitation experiments using
different pRB mutants (defective in
E2F- and/or LxCxE-binding) and iden-
tification of the interacting proteins by
mass spectrometry may help uncover
the multitude of tasks that pRB can
perform to suppress tumorigenesis.
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Figure 1. The retinoblastoma protein, pRB, engages in parallel pathways to suppress tumorigenesis.
The upper section shows the domain structure of pRB. A, B, and C indicate interacting domains. The
middle section indicates interactions between pRB and the E2F family of transcription factors (E2F),
LxCxE-containing proteins (harboring a leucine-x-cysteine-x-glutamic acid motif in which x is any
amino acid), or unknown proteins. The lower section describes the functional consequences of
these interactions.
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